Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use
- 1 May 1994
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 96 (5) , 451-456
- https://doi.org/10.1016/0002-9343(94)90172-4
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Two New Therapies Available Under Treatment INDPublished by American Medical Association (AMA) ,1992
- Angiotensin‐converting enzyme inhibitors, an embryopathic class of drugs with unique properties: Information for clinical teratology counselorsTeratology, 1991
- Maternotoxicity and fetotoxicity of an angiotensin-converting enzyme inhibitor, enalapril, in rabbitsFundamental and Applied Toxicology, 1990
- Enalapril and Pregnancy-Induced HypertensionAnnals of Internal Medicine, 1988
- Treatment of Hypertension in Pregnancy by a Combined Drug Regimen Including CaptoprilClinical and Experimental Hypertension. Part B: Hypertension in Pregnancy, 1986
- Hypertension in PregnancyNew England Journal of Medicine, 1985
- Effect of Captopril on Uterine Blood Flow and Prostaglandin E Synthesis in the Pregnant RabbitJournal of Clinical Investigation, 1983
- Control of vascular responsiveness during human pregnancyKidney International, 1980
- POSSIBLE RISK WITH CAPTOPRIL IN PREGNANCY: SOME ANIMAL DATAThe Lancet, 1980
- Plasma renin activity during ovine pregnancyAmerican Journal of Physiology-Legacy Content, 1975